Invasive pulmonary aspergillosis after treatment with tocilizumab in a patient with COVID-19 ARDS: a case report

Tocilizumab, an interleukin-6 receptor antagonist, has been used to treat critically ill patients with coronavirus disease-2019. We present the case of a previously immunocompetent man with coronavirus disease-2019 who developed invasive pulmonary aspergillosis after treatment with tocilizumab, illu...

Descripción completa

Detalles Bibliográficos
Autores principales: Witting, Celeste, Quaggin-Smith, Jessica, Mylvaganam, Ruben, Peigh, Graham, Angarone, Michael, Flaherty, James D.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Elsevier Inc. 2021
Materias:
Clinical Studies
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7677089/
https://www.ncbi.nlm.nih.gov/pubmed/33388572
http://dx.doi.org/10.1016/j.diagmicrobio.2020.115272
_version_ 1783611907778805760
author Witting, Celeste
Quaggin-Smith, Jessica
Mylvaganam, Ruben
Peigh, Graham
Angarone, Michael
Flaherty, James D.
author_facet Witting, Celeste
Quaggin-Smith, Jessica
Mylvaganam, Ruben
Peigh, Graham
Angarone, Michael
Flaherty, James D.
author_sort Witting, Celeste
collection PubMed
description Tocilizumab, an interleukin-6 receptor antagonist, has been used to treat critically ill patients with coronavirus disease-2019. We present the case of a previously immunocompetent man with coronavirus disease-2019 who developed invasive pulmonary aspergillosis after treatment with tocilizumab, illustrating the importance of considering opportunistic infections when providing immune modulating therapy.
format Online
Article
Text
id pubmed-7677089
institution National Center for Biotechnology Information
language English
publishDate 2021
publisher Elsevier Inc.
record_format MEDLINE/PubMed
spelling pubmed-76770892020-11-20 Invasive pulmonary aspergillosis after treatment with tocilizumab in a patient with COVID-19 ARDS: a case report Witting, Celeste Quaggin-Smith, Jessica Mylvaganam, Ruben Peigh, Graham Angarone, Michael Flaherty, James D. Diagn Microbiol Infect Dis Clinical Studies Tocilizumab, an interleukin-6 receptor antagonist, has been used to treat critically ill patients with coronavirus disease-2019. We present the case of a previously immunocompetent man with coronavirus disease-2019 who developed invasive pulmonary aspergillosis after treatment with tocilizumab, illustrating the importance of considering opportunistic infections when providing immune modulating therapy. Elsevier Inc. 2021-04 2020-11-20 /pmc/articles/PMC7677089/ /pubmed/33388572 http://dx.doi.org/10.1016/j.diagmicrobio.2020.115272 Text en © 2020 Elsevier Inc. All rights reserved. Since January 2020 Elsevier has created a COVID-19 resource centre with free information in English and Mandarin on the novel coronavirus COVID-19. The COVID-19 resource centre is hosted on Elsevier Connect, the company's public news and information website. Elsevier hereby grants permission to make all its COVID-19-related research that is available on the COVID-19 resource centre - including this research content - immediately available in PubMed Central and other publicly funded repositories, such as the WHO COVID database with rights for unrestricted research re-use and analyses in any form or by any means with acknowledgement of the original source. These permissions are granted for free by Elsevier for as long as the COVID-19 resource centre remains active.
spellingShingle Clinical Studies
Witting, Celeste
Quaggin-Smith, Jessica
Mylvaganam, Ruben
Peigh, Graham
Angarone, Michael
Flaherty, James D.
Invasive pulmonary aspergillosis after treatment with tocilizumab in a patient with COVID-19 ARDS: a case report
title Invasive pulmonary aspergillosis after treatment with tocilizumab in a patient with COVID-19 ARDS: a case report
title_full Invasive pulmonary aspergillosis after treatment with tocilizumab in a patient with COVID-19 ARDS: a case report
title_fullStr Invasive pulmonary aspergillosis after treatment with tocilizumab in a patient with COVID-19 ARDS: a case report
title_full_unstemmed Invasive pulmonary aspergillosis after treatment with tocilizumab in a patient with COVID-19 ARDS: a case report
title_short Invasive pulmonary aspergillosis after treatment with tocilizumab in a patient with COVID-19 ARDS: a case report
title_sort invasive pulmonary aspergillosis after treatment with tocilizumab in a patient with covid-19 ards: a case report
topic Clinical Studies
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7677089/
https://www.ncbi.nlm.nih.gov/pubmed/33388572
http://dx.doi.org/10.1016/j.diagmicrobio.2020.115272
work_keys_str_mv AT wittingceleste invasivepulmonaryaspergillosisaftertreatmentwithtocilizumabinapatientwithcovid19ardsacasereport
AT quagginsmithjessica invasivepulmonaryaspergillosisaftertreatmentwithtocilizumabinapatientwithcovid19ardsacasereport
AT mylvaganamruben invasivepulmonaryaspergillosisaftertreatmentwithtocilizumabinapatientwithcovid19ardsacasereport
AT peighgraham invasivepulmonaryaspergillosisaftertreatmentwithtocilizumabinapatientwithcovid19ardsacasereport
AT angaronemichael invasivepulmonaryaspergillosisaftertreatmentwithtocilizumabinapatientwithcovid19ardsacasereport
AT flahertyjamesd invasivepulmonaryaspergillosisaftertreatmentwithtocilizumabinapatientwithcovid19ardsacasereport

Ejemplares similares